메뉴 건너뛰기
Japanese Journal of Antibiotics
Volumn 66, Issue 2, 2013, Pages 97-109
Safety and pharmacokinetics of 400 and 600 mg arbekacin sulfate to healthy male volunteers
Author keywords

[No Author keywords available]
Indexed keywords

HABEKACIN;
EID: 84877986970     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)
References (28)
  • 1
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
    • (1998) Clin. Infect. Dis. , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 2
    • 0024441288 scopus 로고
    • Determinants of efficacy and toxicity of aminoglycosides
    • MATTIE, H.; W. A. CRAIG, et al.: Determinants of efficacy and toxicity of aminoglycosides. J. Antimicrob. Chemother. 24: 281-293, 1989
    • (1989) J. Antimicrob. Chemother. , vol.24 , pp. 281-293
    • Mattie, H.1    Craig, W.A.2
  • 3
    • 0031965768 scopus 로고    scopus 로고
    • Population pharmacokinetics of vancomycin in Japanese adult patients
    • YASUHARA, M.; T. IGA, et al.: Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit. 20: 139-148, 1998
    • (1998) Ther. Drug Monit. , vol.20 , pp. 139-148
    • Yasuhara, M.1    Iga, T.2
  • 4
    • 0036781257 scopus 로고    scopus 로고
    • Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters
    • TERAMACHI, H.; H. HATAKEYAMA, R. MATSUSHITA, et al.: Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol. Pharm. Bull. 25: 1333-1338, 2002
    • (2002) Biol. Pharm. Bull. , vol.25 , pp. 1333-1338
    • Teramachi, H.1    Hatakeyama, H.2    Matsushita, R.3
  • 5
    • 84877982640 scopus 로고    scopus 로고
    • Japanese source
  • 6
    • 84877979492 scopus 로고    scopus 로고
    • Japanese source
  • 7
    • 84877964606 scopus 로고    scopus 로고
    • Japanese source
  • 8
    • 84877997287 scopus 로고    scopus 로고
    • Japanese source
  • 9
    • 84877991214 scopus 로고    scopus 로고
    • Japanese source
  • 10
    • 0032991320 scopus 로고    scopus 로고
    • Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?
    • BARCLAY, M. L.; C. M. KIRKPATRICK & E. J. BEGG: Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin. Pharmacokinet. 36: 89-98, 1999
    • (1999) Clin. Pharmacokinet. , vol.36 , pp. 89-98
    • Barclay, M.L.1    Kirkpatrick, C.M.2    Begg, E.J.3
  • 11
    • 84878001734 scopus 로고    scopus 로고
    • Japanese source
  • 12
    • 84877976843 scopus 로고    scopus 로고
    • Japanese source
  • 13
    • 84878000564 scopus 로고    scopus 로고
    • Japanese source
  • 14
    • 84877962799 scopus 로고    scopus 로고
    • Japanese source
  • 15
    • 84877954619 scopus 로고    scopus 로고
    • Japanese source
  • 17
    • 33750589806 scopus 로고    scopus 로고
    • Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus
    • TANIGAWARA, Y.; R. SATO, K. MORITA, et al.: Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3754-3762, 2006
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 3754-3762
    • Tanigawara, Y.1    Sato, R.2    Morita, K.3
  • 18
    • 33750593916 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus
    • SATO, R.; Y. TANIGAWARA, M. KAKU, et al.: Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3763-3769, 2006
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 3763-3769
    • Sato, R.1    Tanigawara, Y.2    Kaku, M.3
  • 19
    • 84877934649 scopus 로고    scopus 로고
    • Japanese source
  • 20
    • 84877951148 scopus 로고    scopus 로고
    • Japanese source
  • 21
    • 84877968537 scopus 로고    scopus 로고
    • Japanese source
  • 22
    • 84877990616 scopus 로고    scopus 로고
    • Japanese source
  • 23
    • 84885370237 scopus 로고    scopus 로고
    • Jpn. J. Chemother. 60: 393-445, 2012
    • (2012) Jpn. J. Chemother. , vol.60 , pp. 393-445
  • 24
    • 84877957248 scopus 로고    scopus 로고
    • Japanese source
  • 25
    • 84877981744 scopus 로고    scopus 로고
    • Japanese source
  • 26
    • 84863326417 scopus 로고    scopus 로고
    • The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection
    • YAMAMOTO, Y.; K. IZUMIKAWA, K. HASHIGUCHI, et al.: The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J. Infect. Chemother. 18: 241-246, 2012
    • (2012) J. Infect. Chemother. , vol.18 , pp. 241-246
    • Yamamoto, Y.1    Izumikawa, K.2    Hashiguchi, K.3
  • 27
    • 84874108462 scopus 로고    scopus 로고
    • Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: A multi-institutional study
    • MATSUMOTO, T.; H. HANAKI, T. KIMURA, et al.: Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: A multi-institutional study. J. Infect. Chemother. 19: 128-137, 2013
    • (2013) J. Infect. Chemother. , vol.19 , pp. 128-137
    • Matsumoto, T.1    Hanaki, H.2    Kimura, T.3
  • 28
    • 84866421309 scopus 로고    scopus 로고
    • Jpn. J. Antibiotics 65: 263-269, 2012
    • (2012) Jpn. J. Antibiotics , vol.65 , pp. 263-269

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.